track sports

track sports How to watch Portland Trail Blazers vs. Utah Jazz: Live stream, TV channel, start time for Thursday's NBA gameAzerbaijani and US officials believe a Russian surface-to-air missile caused the deadly crash of an Azerbaijani passenger jet, media reports and a US official said Thursday, as the Kremlin cautioned against "hypotheses" over the disaster. The Azerbaijan Airlines jet crashed near the Kazakh city of Aktau, an oil and gas hub, on Wednesday after going off course for undetermined reasons. Thirty-eight of the 67 people on board died. The Embraer 190 aircraft was supposed to fly northwest from the Azerbaijani capital Baku to the city of Grozny in Chechnya, southern Russia, but instead diverted far off course across the Caspian Sea. An investigation is underway, with pro-government Azerbaijani website Caliber citing unnamed officials as saying they believed a Russian missile fired from a Pantsir-S air defence system downed the plane. The claim was also reported by The New York Times, broadcaster Euronews and the Turkish news agency Anadolu. Some aviation and military experts said the plane might have been accidentally shot by Russian air defence systems because it was flying in an area where Ukrainian drone activity had been reported. A former expert at France's BEA air accident investigation agency said there appeared to be "a lot of shrapnel" damage on the wreckage. Speaking on condition of anonymity, he said the damage was "reminiscent" of Malaysia Airlines flight MH17, which was downed with a surface-to-air missile by Russia-backed rebels over eastern Ukraine in 2014. Kremlin spokesman Dmitry Peskov told reporters: "It would be wrong to make any hypotheses before the investigation's conclusions." Euronews cited Azerbaijani government sources as saying that "shrapnel hit the passengers and cabin crew as it exploded next to the aircraft mid-flight". A US official, speaking on condition of anonymity, also said early indications suggested a Russian anti-aircraft system struck the plane. Kazakhstan news agency Kazinform cited a regional prosecutor as saying that two black-box flight recorders had been recovered. Azerbaijan Airlines initially said the plane flew through a flock of birds, before withdrawing the statement. Kazakh officials said 38 people had been killed and there were 29 survivors, including three children. Jalil Aliyev, the father of flight attendant Hokume Aliyeva, told AFP that this was supposed to have been her last flight before starting a job as a lawyer for the airline. "Why did her young life have to end so tragically?" the man said in a trembling voice before hanging up the phone. Eleven of the injured are in intensive care, the Kazakh health ministry said. Azerbaijani President Ilham Aliyev declared Thursday a day of mourning and cancelled a planned visit to Russia for an informal summit of the Commonwealth of Independent States (CIS), a grouping of former Soviet nations. "I extend my condolences to the families of those who lost their lives in the crash... and wish a speedy recovery to the injured," Aliyev said in a social media post Wednesday. The Flight Radar website showed the plane deviating from its normal route, crossing the Caspian Sea and then circling over the area where it eventually crashed near Aktau, on the eastern shore of the sea. Kazakhstan said the plane was carrying 37 Azerbaijani passengers, six Kazakhs, three Kyrgyz and 16 Russians. A Kazakh woman told the local branch of Radio Free Europe/Radio Liberty (RFE/RL) she was near where the plane crashed and rushed to the site to help survivors. "They were covered in blood. They were crying. They were calling for help," said the woman, who gave her name as Elmira. She said they saved some teenagers. "I'll never forget their look, full of pain and despair," said Elmira. "A girl pleaded: 'Save my mother, my mother is back there'." Russian President Vladimir Putin held a phone conversation with Aliyev and "expressed his condolences in connection with the crash", Peskov told a news conference. bur/rlp/js

Russia missile suspected in Azerbaijani plane crash, Moscow warns against 'hypotheses'Self-Locking Circuit Breaker Lockout: Enhancing Workplace Safety via LOTO

Belagavi Session: CWC demands end to tax terrorism, wants Budget to give relief to poor and middle classes

Unrivaled Brands (OTCMKTS:TRTC) Stock Price Passes Below 50-Day Moving Average – Should You Sell?Best sportsbook promo codes for Thursday Night Football: Dec. 26

Pre-Collision System (PCS) Market Outlook and Future Projections for 2030Royals of Udaipur are in street-fight mode. Ex-monarchs make for good entertainment In Udaipur, a feud between former royals has spilled into street fight. A newly crowned ‘maharana’ and legislator seeks blessings from a family shrine, but is being blocked by his uncle and cousin, to whom the palace trust has been willed by the late ‘maharana’. Kaboom, as the cartoons would put it. The Mewar battle royale is only one of many fierce disputes among India’s feudal families. From Rajkot to Baroda to Gwalior to Sirmaur, legal wrangles and strained relations are common, given the significant wealth these families still hold. Their glory days are – thank god – over. But property, jewellery and defunct titles are still high-stakes enough for vicious skirmishes. Why? Because royals are families too, and like any other brood with something to fight over, they do. History could be seen as a long scroll of familial love and hate – from the pharaohs to the Tudors, the Habsburgs or Pahlavis and Romanovs, the fate of great cities and empires and even religions has been entwined with family politics. In India, the golden age of miscellaneous maharajahs was between the 18th and 20th centuries after Mughal power waned. They collaborated with Brits in a two-tier ruling class. Some were extractive, some have been portrayed as benefactors, or modernisers. But like anyone else, they fought and made peace with their circumstances. When India moved from Raj to republic, they had to merge with the Union. In 1971, they lost their titles and fabulous privy purses. Some royals have converted their feudal charisma into electoral capital. Some have turned their palaces into heritage hospitality. Some are aristocratic influencers, selling visions of the high life. Everywhere in the democratic world, former royals are a faded reminder of bygone days, and fodder for gossip. In the constitutional monarchies of Britain, Holland and northern Europe, they have apolitical, ceremonial roles rather than sovereign aura. Their public work may be duty and drudgery, but their escapades, affairs and tiffs are of consuming interest to much of the public. Something lingers from the old days, where the king could be a sacred figure or a scapegoat. And even today, whether you love them or they raise your republican hackles, royals certainly make a spectacle. And even in a democracy, where we are counted in our numbers rather than weighed by rank, we’re still riveted by palace entertainment. Royals make for excellent reality TV, it turns out.

Barclays PLC increased its position in Select Water Solutions, Inc. ( NYSE:WTTR – Free Report ) by 319.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 140,648 shares of the company’s stock after buying an additional 107,107 shares during the period. Barclays PLC owned 0.12% of Select Water Solutions worth $1,565,000 at the end of the most recent quarter. A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in WTTR. Innealta Capital LLC purchased a new stake in shares of Select Water Solutions during the 2nd quarter worth approximately $34,000. GAMMA Investing LLC grew its holdings in shares of Select Water Solutions by 37.9% in the third quarter. GAMMA Investing LLC now owns 4,149 shares of the company’s stock valued at $46,000 after purchasing an additional 1,141 shares in the last quarter. New York State Teachers Retirement System increased its position in Select Water Solutions by 13.8% in the third quarter. New York State Teachers Retirement System now owns 8,327 shares of the company’s stock worth $93,000 after purchasing an additional 1,010 shares during the last quarter. Northwest & Ethical Investments L.P. purchased a new stake in Select Water Solutions during the third quarter valued at $107,000. Finally, Creative Planning bought a new position in Select Water Solutions during the third quarter valued at $112,000. 81.73% of the stock is owned by institutional investors. Select Water Solutions Stock Performance Shares of NYSE:WTTR opened at $12.83 on Friday. The firm has a fifty day simple moving average of $13.11 and a two-hundred day simple moving average of $11.70. Select Water Solutions, Inc. has a 52 week low of $6.99 and a 52 week high of $15.14. The company has a quick ratio of 1.62, a current ratio of 1.78 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $1.53 billion, a P/E ratio of 21.75 and a beta of 1.76. Select Water Solutions Increases Dividend The business also recently announced a quarterly dividend, which was paid on Friday, November 15th. Stockholders of record on Tuesday, November 5th were given a dividend of $0.07 per share. The ex-dividend date of this dividend was Tuesday, November 5th. This represents a $0.28 annualized dividend and a dividend yield of 2.18%. This is an increase from Select Water Solutions’s previous quarterly dividend of $0.06. Select Water Solutions’s payout ratio is currently 47.46%. About Select Water Solutions ( Free Report ) Select Water Solutions, Inc, together with its subsidiaries, provides water management and chemical solutions to the energy industry in the United States. The company operates through three segments: Water Services, Water Infrastructure, and Chemical Technologies. The Water Services segment provides water-related services, including water sourcing, water transfer, flowback and well testing, water containment, fluids hauling, water monitoring, and water network automation; technology solutions comprising hydrographic mapping, water volume and quality monitoring, remote pit and tank monitoring, leak detection, asset and fuel tracking, and automated-equipment services, as well as various surface rental equipment and workforce accommodation services. Read More Five stocks we like better than Select Water Solutions Stock Market Upgrades: What Are They? S&P 500 ETFs: Expense Ratios That Can Boost Your Long-Term Gains What Are Trending Stocks? Trending Stocks Explained How AI Implementation Could Help MongoDB Roar Back in 2025 The Significance of Brokerage Rankings in Stock Selection Hedge Funds Boost Oil Positions: Is a Major Rally on the Horizon? Receive News & Ratings for Select Water Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Select Water Solutions and related companies with MarketBeat.com's FREE daily email newsletter .According to DelveInsight's analysis, the market for Down syndrome is anticipated to increase during the forecast period (2024–2034), owing to the launch of emerging therapies such as AEF0217, ACI-24.060, LEUCETTINIB-21, BUNTANETAP, and others and healthcare spending globally. LAS VEGAS , Nov. 26, 2024 /PRNewswire/ -- DelveInsight's Down's Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Down's syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [ the United States , the EU4 ( Germany , France , Italy , and Spain ) and the United Kingdom , and Japan ]. Key Takeaways from the Down's Syndrome Market Report According to DelveInsight's analysis, the market size for Down's syndrome was found to be USD 241 million in the US in 2023. In 2023, the United States accounted for nearly 220K prevalent cases of Down's syndrome. The types of Down's syndrome include Trisomy 21, Robertsonian translocation, and Mosaicism. In 2023, among all types, Trisomy 21 accounted for the highest number of prevalent cases in the 7MM. Leading Down's syndrome companies such as AELIS FARMA, AC IMMUNE, PERHA PHARMACEUTICALS, ANNOVIS BIO, APHIOS THERAPEUTICS, and others are developing novel Down's syndrome drugs that can be available in the Down's syndrome market in the coming years. The promising Down's syndrome therapies in the pipeline include AEF0217, ACI-24.060, LEUCETTINIB-21, BUNTANETAP, APH-1104, and others. Discover which therapies are expected to grab the major Down's syndrome market share @ Down's Syndrome Market Report Down's Syndrome Overview Down's syndrome, also known as trisomy 21, is a genetic disorder caused by the presence of an extra copy of chromosome 21. This chromosomal anomaly disrupts normal development, resulting in a range of physical and cognitive differences. The condition is primarily caused by random genetic mutations during the formation of reproductive cells or early embryonic development, though advanced maternal age increases the likelihood of having a child with Down's syndrome. People with Down's syndrome typically exhibit distinct facial features, such as a flattened face, almond-shaped eyes that slant upward, and a small nose. Other common symptoms include developmental delays, intellectual disabilities, and a variety of health issues like heart defects, respiratory and hearing problems, and a higher susceptibility to infections. Despite these challenges, many individuals with Down's syndrome lead fulfilling lives with appropriate support. Diagnosis of Down's syndrome can occur prenatally through screening and diagnostic tests, such as blood tests and ultrasounds in the first and second trimesters, or through more definitive tests like chorionic villus sampling (CVS) and amniocentesis. Postnatal diagnosis is typically confirmed by a physical examination and a karyotype analysis to identify the extra chromosome. Early diagnosis and intervention can help address developmental needs and improve the quality of life for individuals with Down's syndrome. Down's Syndrome Epidemiology Segmentation The Down's syndrome epidemiology section provides insights into the historical and current Down's syndrome patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The Down's syndrome market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Diagnosed Prevalent Cases of Down's Syndrome Gender-specific Diagnosed Prevalent Cases of Down's Syndrome Type-specific Diagnosed Prevalent Cases of Down's Syndrome Age-specific Diagnosed Prevalent Cases of Down's Syndrome Diagnosed Cases of Down's Syndrome by Clinical Manifestations Down's Syndrome Treatment Market There is no single treatment for Down's syndrome; instead, care plans are customized to address each person's unique physical and intellectual needs, emphasizing their strengths and accommodating their limitations. For some individuals, immediate surgery may be needed after birth to correct heart defects or long-term dietary modifications may be required for digestive concerns. Common interventions include assistive devices such as hearing aids, mobility aids, and adaptive technology to support learning and daily tasks. People with Down's syndrome often face an earlier and more pronounced cognitive decline than the general population. Treatments for Down syndrome-associated dementia (DSAD) may include medications like rivastigmine, galantamine, memantine, and donepezil, which inhibit acetylcholine breakdown, providing notable benefits. Seizure management for those with Down syndrome may involve anticonvulsants like carbamazepine and phenytoin, although these can exacerbate other Down syndrome-related issues. Respiratory problems are also common due to immune deficiencies and respiratory tract abnormalities, often requiring antibiotics or inhaled bronchodilators for effective management. Along with pharmacological treatments, non-pharmacological therapies such as physical, speech, occupational, and behavioral therapies play a vital role in the early development of children with Down syndrome, promoting independence and productivity. Physical therapy aims to improve motor skills, build muscle strength, and enhance posture and balance, laying the groundwork for key abilities. Speech-language therapy focuses on boosting communication skills and addressing physical challenges like low muscle tone to avoid long-term complications. Occupational therapy adapts daily tasks to suit the individual's abilities, teaching crucial skills such as eating, dressing, writing, and using a computer. Emotional and behavioral therapies tackle challenges like frustration from communication barriers, compulsive behaviors, and ADHD by identifying triggers and creating strategies to foster positive behaviors and reduce undesirable ones. To know more about Down's syndrome treatment guidelines, visit @ Down's Syndrome Management Down's Syndrome Pipeline Therapies and Key Companies AEF0217: AELIS FARMA ACI-24.060: AC IMMUNE LEUCETTINIB-21: PERHA PHARMACEUTICALS BUNTANETAP: ANNOVIS BIO APH-1104: APHIOS THERAPEUTICS Discover more about Down's syndrome drugs in development @ Down's Syndrome Clinical Trials Down's Syndrome Market Dynamics The Down's syndrome market dynamics are expected to change in the coming years. The prevalence of Down syndrome has increased with the rise in lifespan over the past three decades. This, along with the combination of several neurological features in Down syndrome patients—such as language impairment, cognition, learning, and memory—has sparked intense neurodevelopmental research. Studies in this area hold promise for improving clinical care and quality of life for individuals with Down syndrome and their families, as well as for assessing ways to enhance communication between parents and children. A thorough understanding of the factors affecting pharmacotherapy in Down syndrome could significantly contribute to better clinical outcomes for these individuals. Furthermore, potential therapies are being investigated for the treatment of Down's syndrome, and it is safe to predict that the treatment space will significantly impact the Down's syndrome market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the Down's syndrome market in the 7MM. However, several factors may impede the growth of the Down's syndrome market. Down syndrome presents unique challenges in clinical treatment, as there is currently no medical cure or approved products available in the market, complicating the treatment process. This complexity is compounded by the lack of appropriate, validated scales to measure progress or side effects in participants with learning disabilities, making it difficult to gauge treatment impact effectively. Furthermore, recruiting participants and their families is challenging, adding to the difficulties in conducting research. Down syndrome is also associated with numerous health problems and high healthcare costs , and individuals may require more intensive monitoring for adverse effects, adherence, and treatment efficacy when managing medications. Conducting clinical studies on the efficacy of psychotropic medications in individuals with Down syndrome is particularly challenging due to the unique language and communication characteristics of this population. Moreover, Down's syndrome treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, Down's syndrome market growth may be offset by failures and discontinuation of emerging therapies , unaffordable pricing , market access and reimbursement issues , and a shortage of healthcare specialists . In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact Down's syndrome market growth. Down's Syndrome Market Report Metrics Details Study Period 2020–2034 Coverage 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. Down's Syndrome Market CAGR 3.81 % Down's Syndrome Market Size in the US in 2023 USD 241 Million Key Down's Syndrome Companies AELIS FARMA, AC IMMUNE, PERHA PHARMACEUTICALS, ANNOVIS BIO, APHIOS THERAPEUTICS, and others Key Pipeline Down's Syndrome Therapies AEF0217, ACI-24.060, LEUCETTINIB-21, BUNTANETAP, APH-1104, and others Scope of the Down's Syndrome Market Report Therapeutic Assessment: Down's Syndrome current marketed and emerging therapies Down's Syndrome Market Dynamics: Key Market Forecast Assumptions of Emerging Down's Syndrome Drugs and Market Outlook Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Down's Syndrome Market Access and Reimbursement Download the report to understand which factors are driving Down's syndrome market trends @ Down's Syndrome Market Trends Table of Contents 1 KEY INSIGHTS 2 REPORT INTRODUCTION 3 EXECUTIVE SUMMARY OF DOWN'S SYNDROME 4 DOWN'S SYNDROME MARKET OVERVIEW AT A GLANCE 4.1 MARKET SHARE BY THERAPIES (%) DISTRIBUTION OF DOWN'S SYNDROME IN 2020 IN THE 7MM 4.2 MARKET SHARE BY THERAPIES (%) DISTRIBUTION OF DOWN'S SYNDROME IN 2034 IN THE 7MM 5 KEY EVENTS 6 EPIDEMIOLOGY AND MARKET FORECAST METHODOLOGY 7 DOWN'S SYNDROME: DISEASE BACKGROUND AND OVERVIEW 7.1 INTRODUCTION 7.2 ETIOLOGY 7.3 TYPES OF DOWN'S SYNDROME 7.3.1 Trisomy 21 7.3.2 Translocation Down's syndrome 7.3.3 Mosaic Down's syndrome 7.4 CAUSES AND RISK FACTORS 7.5 COMPLICATIONS 7.6 OTHER HEALTH PROBLEMS 7.7 DIAGNOSIS 7.7.1 Screening Tests 7.7.2 Diagnostic Tests 7.8 TREATMENTS 7.8.1 Early Intervention and Educational Therapy 7.8.2 Treatment Therapies 7.8.3 Drugs and Supplements 7.8.4 Assistive Devices 8 CASE REPORTS 8.1 CASE STUDY: AN IPP TEAM HELPS 6-YEAR WITH DOWN'S SYNDROME IMPROVE COMMUNICATION SKILLS 9 EPIDEMIOLOGY AND PATIENT POPULATION 9.1 KEY FINDINGS 9.2 ASSUMPTIONS AND RATIONALE 9.3 TOTAL PREVALENT CASES OF DOWN'S SYNDROME IN THE 7MM 9.4 TYPE-SPECIFIC CASES OF DOWN'S SYNDROME IN THE 7MM 9.5 GENDER-SPECIFIC CASES OF DOWN'S SYNDROME IN THE 7MM 9.6 PREVALENT CASES OF DOWN'S SYNDROME BY CLINICAL MANIFESTATIONS IN THE 7MM 9.7 PREVALENT CASES OF DOWN'S SYNDROME BY AGE IN THE 7MM 9.8 THE UNITED STATES 9.8.1 Total Prevalent Cases of Down's Syndrome in the US 9.8.2 Type-specific Cases of Down's Syndrome in the US 9.8.3 Gender-specific Cases of Down's Syndrome in the US 9.8.4 Prevalent cases of Down's Syndrome by clinical manifestations in the US 9.8.5 Prevalent cases of Down's Syndrome by Age in the US 9.9 EU4 AND THE UK 9.9.1 Total Prevalent Cases of Down's syndrome in EU4 and the UK 9.9.2 Type-specific Cases of Down's syndrome in EU4 and the UK 9.9.3 Gender-specific Cases of Down's syndrome in EU4 and the UK 9.9.4 Prevalent cases of Down's syndrome by clinical manifestations in EU4 and the UK 9.9.5 Prevalent cases of Down's syndrome by Age in EU4 and the UK 9.10 JAPAN 9.10.1 Total Prevalent Cases of Down's syndrome in Japan 9.10.2 Type-specific Cases of Down's syndrome in Japan 9.10.3 Gender-specific Cases of Down's syndrome in Japan 9.10.4 Prevalent cases of Down's syndrome by clinical manifestations in Japan 9.10.5 Prevalent cases of Down's syndrome by Age in Japan 10 PATIENT JOURNEY 11 EMERGING DRUGS 11.1 KEY COMPETITORS 11.2 AEF0217: AELIS FARMA 11.2.1 Product Description 11.2.2 Other Developmental Activities 11.2.3 Clinical Development 11.2.3.1 Clinical Trials Information 11.2.4 Safety and Efficacy 11.3 ACI-24.060: AC IMMUNE 11.3.1 Product Description 11.3.2 Clinical Development 11.3.2.1 Clinical Trials Information 11.3.3 Safety and Efficacy 11.4 LEUCETTINIB-21: PERHA PHARMACEUTICALS 11.4.1 Product Description 11.4.2 Clinical Development 11.4.2.1 Clinical Trials Information 11.4.3 Other Developmental Activities 11.4.4 Safety and Efficacy 11.5 BUNTANETAP: ANNOVIS BIO 11.5.1 Product Description 11.5.2 Other Developmental Activities 11.5.3 Safety and Efficacy 11.6 APH-1104: APHIOS THERAPEUTICS 11.6.1 Product Description 11.6.2 Other Developmental Activities 12 DOWN'S SYNDROME: MARKET ANALYSIS 12.1 KEY FINDINGS 12.2 MARKET OUTLOOK 12.3 CONJOINT ANALYSIS 12.4 KEY MARKET FORECAST ASSUMPTIONS 12.5 TOTAL MARKET SIZE OF DOWN'S SYNDROME IN THE 7MM 12.6 UNITED STATES MARKET SIZE 12.6.1 Total Market Size of Down's Syndrome in the United States 12.6.2 Market Size of Down's Syndrome by Therapies in the United States 12.7 EU4 AND THE UK MARKET SIZE 12.7.1 Total Market Size of Down's Syndrome in EU4 and the UK 12.7.2 Market Size of Down's Syndrome by Therapies in EU4 and the UK 12.8 JAPAN MARKET SIZE 12.8.1 Total Market Size of Down's Syndrome in Japan 12.8.2 Market Size of Down's Syndrome by Therapies in Japan 13 UNMET NEEDS 14 SWOT ANALYSIS 15 MARKET ACCESS AND REIMBURSEMENT 15.1 UNITED STATES 15.1.1 Centre for Medicare & Medicaid Services (CMS) 15.2 EU4 AND THE UK 15.2.1 Germany 15.2.2 France 15.2.3 Italy 15.2.4 Spain 15.2.5 United Kingdom 15.3 JAPAN 15.3.1 MHLW 16 APPENDIX 16.1 BIBLIOGRAPHY 16.2 REPORT METHODOLOGY 17 DELVEINSIGHT CAPABILITIES 18 DISCLAIMER 19 ABOUT DELVEINSIGHT Related Reports Down's Syndrome Epidemiology Forecast Down's Syndrome Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Down's syndrome epidemiology trends. Down's Syndrome Pipeline Down's Syndrome Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Down's syndrome companies, including Alzheon, Inc, Connecta Therapeutics, among others. Alport Syndrome Market Alport Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alport syndrome companies, including Eloxx Pharmaceuticals, Chinook Therapeutics (A Novartis company), Bayer, Calliditas Therapeutics, Evotec , among others. Alport Syndrome Pipeline Alport Syndrome Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Alport syndrome companies, including Eloxx Pharmaceuticals, Inc., Chinook Therapeutic/Novartis, River 3 Renal Corp., Travere Therapeutics, Inc., Reata Pharmaceuticals, Inc., among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur info@delveinsight.com +14699457679 www.delveinsight.com Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

AP News Summary at 1:24 p.m. ESTIn 2024, curiosity was as intense as a solar eclipse—or even more so. The top Google searches of 2024 reveal a world grappling with major events and everyday mysteries, whether understanding celestial phenomena, untangling political controversies, or keeping up with pop culture. Here are Canadian's most searched "what", "why" and "how" according to Google Trends. In the "What" category, the skies—and the screens—dominated our attention. The most pressing question was, “What time is the solar eclipse?” as people worldwide didn’t want to miss the rare event. Combat sports lovers wanted to know “What time is the Jake Paul vs. Mike Tyson fight?” —an unusual clash of generations. Political intrigue was high with “What is Project 2025?” and “What time is the Presidential debate?” showing the upcoming election’s impact. Meanwhile, concerns about health, language, and technology appeared with questions like “What is Mpox?” , “What does demure mean?” , and “What is CrowdStrike?” The "Why" questions suggest a year of global conflicts, pop culture intrigue, and societal shifts. People sought explanations for pivotal events, from solar safety ( “Why can’t you look at a solar eclipse?” ) to political outcomes ( “Why did Trump win?”). Drake’s influence continued with “Why is Drake trending?” while geopolitical crises drove queries like “Why did Israel attack the Iranian embassy?” and “Why did ISIS attack Moscow?” On a lighter note, Canadian sports fans wanted to know “Why is Nylander not playing?” —a question underscoring the nation’s hockey fervour. The "How" list reflected practical concerns and a thirst for knowledge. Civic-minded searches like “How many electoral votes are there?” and “How to register to vote in the US?” led the charge. Sports remained a priority with “How to watch the Olympics in Canada?” and “How many Canadians on the Florida Panthers?” Health-related questions included “How does being barefoot affect your health?” Meanwhile, the eclipse generated queries like “How long will the eclipse last?” and “How to make solar eclipse glasses?” These top searches reflect a world where people want to be informed, prepared, and entertained—whether by an eclipse, a debate, or a celebrity headline.

Kingfield students engage in hands-on activities

Shannon Sharpe has revealed a private conversation with Kirk Herbstreit following a disagreement between the two ESPN broadcasters over college football. The dispute arose from differing opinions on the current state of the Ohio State Buckeyes , and it seems the fallout has extended beyond just football talk. Sharpe had questioned the position of Buckeyes' head coach Ryan Day at Herbstreit's alma mater on First Take. Herbstreit publicly expressed his disapproval of the criticism on First Take, leading to a heated response from Stephen A.Smith and Sharpe. Kirk Herbstreit has 'obvious' explanation for Ohio State dominating Tennessee Shane Gillis torches Nick Saban in awkward College Gameday interaction "First Take tried to fire him, they thought he was done," Herbstreit said about the scrutiny directed at Day. "So I'm excited to see what they talk about on Monday after this performance. "They had him out. They were trying to find replacements. But here he is. He's still got his hat on. He's still coaching." On 'Night Cap' with Chad 'Ochocinco' Johnson, Sharpe discussed the situation with Herbstreit. He shared that they had spoken and Herbstreit had tried to explain his perspective. "My point was, and I don't know if he was talking to me, but I did not think the commentary was warranted," Sharpe said. "Yes, the Buckeyes won. Everyone knows Kirk Herbstreit was schooled at Ohio State. "I believe you can stand up for your friends and alma mater without taking a shot at your teammates. And I felt he was taking a shot at First Take. That's why I'm glad that Herbie reached out. DON'T MISS: Terry Bradshaw given FOX NFL retirement view after Michael Strahan interruption FOX's Tom Brady gamble at risk of backfiring as 'A team' panel slammed Cris Collinsworth's social media rule speaks volumes amid NBC firing calls "We were able to put this whole situation behind us. I know he is happy that Ohio State won and is good friends with Ryan Day. However, being good friends and then taking a shot are different situations. I just needed clarity: Are we teammates or not? That is all I needed to know. Because if we are not teammates, then let's throw caution to the wind." In response to the ex-Ohio State quarterback's statements, Sharpe had previously defended himself on First Take: "I am going to be a teammate. I will let it slide since everyone's at ESPN, especially because you have not taken the rocks you have taken. "I would have lit them up," the three-time Super Bowl champion declared. "Congratulations, Ohio State. You won. However, if we are going to be on the same team or work on the same network, then don't do that. "Kirk, Chris Fowler, I promise you, if you ever mention anything about any platform that I am on again, talking about, I wonder what they are going to say in negativity. I promise you ESPN doesn't have enough bosses to keep me off y'all for what I am going to say." Smith also responded fervently to Herbstreit following his remarks, as he too refuted the accusations against him: "Kirk Herbstreit, 'First Take tried to get him fired.' That is not true. I did. Not First Take. That was me, Stephen A. I'm going to own that," Smith asserted. "And what did I say specifically, Kirk Herbstreit, because you've got to quote me accurately, my brother. I watch you on College Football GameDay. I don't misquote you, don't misquote me. What I said was, this man Ryan Day, if he doesn't get a national championship he should go, even with a 66-10 record."

Guna Borewell Incident: Boy Falls Into Borewell in Madhya Pradesh, Rescue Operation On

NEW YORK (AP) — U.S. stocks rose to records Tuesday after Donald Trump’s latest talk about tariffs created only some ripples on Wall Street, even if they could roil the global economy were they to take effect. The S&P 500 climbed 0.6% to top the all-time high it set a couple weeks ago. The Dow Jones Industrial Average added 123 points, or 0.3%, to its own record set the day before, while the Nasdaq composite gained 0.6% as Microsoft and Big Tech led the way. Stock markets abroad mostly fell after President-elect Trump said he plans to impose sweeping new tariffs on Mexico, Canada and China once he takes office. But the movements were mostly modest. Stock indexes were down 0.1% in Shanghai and nearly flat in Hong Kong, while Canada’s main index edged down by less than 0.1%. Trump has often praised the use of tariffs , but investors are weighing whether his latest threat will actually become policy or is just an opening point for negotiations. For now, the market seems to be taking it more as the latter. The consequences otherwise for markets and the global economy could be painful. Unless the United States can prepare alternatives for the autos, energy products and other goods that come from Mexico, Canada and China, such tariffs would raise the price of imported items all at once and make households poorer, according to Carl Weinberg and Rubeela Farooqi, economists at High Frequency Economics. They would also hurt profit margins for U.S. companies, while raising the threat of retaliatory tariffs by other countries. And unlike tariffs in Trump’s first term, his latest proposal would affect products across the board. General Motors sank 9%, and Ford Motor fell 2.6% because both import automobiles from Mexico. Constellation Brands, which sells Modelo and other Mexican beer brands in the United States, dropped 3.3%. The value of the Mexican peso fell 1.8% against the U.S. dollar. Beyond the pain such tariffs would cause U.S. households and businesses, they could also push the Federal Reserve to slow or even halt its cuts to interest rates. The Fed had just begun easing its main interest rate from a two-decade high a couple months ago to offer support for the job market . While lower interest rates can boost the economy, they can also offer more fuel for inflation. “Many” officials at the Fed’s last meeting earlier this month said they should lower rates gradually, according to minutes of the meeting released Tuesday afternoon. The talk about tariffs overshadowed another mixed set of profit reports from U.S. retailers that answered few questions about how much more shoppers can keep spending. They’ll need to stay resilient after helping the economy avoid a recession, despite the high interest rates imposed by the Fed to get inflation under control. A report on Tuesday from the Conference Board said confidence among U.S. consumers improved in November, but not by as much as economists expected. Kohl’s tumbled 17% after its results for the latest quarter fell short of analysts’ expectations. CEO Tom Kingsbury said sales remain soft for apparel and footwear. A day earlier, Kingsbury said he plans to step down as CEO in January. Ashley Buchanan, CEO of Michaels and a retail veteran, will replace him. Best Buy fell 4.9% after likewise falling short of analysts’ expectations. Dick’s Sporting Goods topped forecasts for the latest quarter thanks to a strong back-to-school season, but its stock lost an early gain to fall 1.4%. Still, more stocks rose in the S&P 500 than fell. J.M. Smucker had one of the biggest gains and climbed 5.7% after topping analysts’ expectations for the latest quarter. CEO Mark Smucker credited strength for its Uncrustables, Meow Mix, Café Bustelo and Jif brands. Big Tech stocks also helped prop up U.S. indexes. Gains of 3.2% for Amazon and 2.2% for Microsoft were the two strongest forces lifting the S&P 500. All told, the S&P 500 rose 34.26 points to 6,021.63. The Dow gained 123.74 to 44,860.31, and the Nasdaq composite climbed 119.46 to 19,174.30. In the bond market, Treasury yields held relatively steady following their big drop from a day before driven by relief following Trump’s pick for Treasury secretary. The yield on the 10-year Treasury inched up to 4.29% from 4.28% late Monday, but it’s still well below the 4.41% level where it ended last week. In the crypto market, bitcoin continued to pull back after topping $99,000 for the first time late last week. It’s since dipped back toward $91,000, according to CoinDesk. It’s a sharp turnaround from the bonanza that initially took over the crypto market following Trump’s election. That boom had also appeared to have spilled into some corners of the stock market. Strategists at Barclays Capital pointed to stocks of unprofitable companies, along with other areas that can be caught up in bursts of optimism by smaller-pocketed “retail” investors. AP Business Writer Elaine Kurtenbach contributed. Copyright 2024 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission. Get the latest local business news delivered FREE to your inbox weekly.

EPL: Ola Aina’s Nottingham Forest Move To 3rd SpotOral Resin Market Outlook and Future Projections for 2030

Unwind from the craziness of the holidays with a little Thursday Night Football on Prime Video! Need something to watch during your holiday break? Decider’s got your back. If you’re looking for an interesting look at controversial quarterback Aaron Rodgers, Netflix’s new documentary is for you. Aaron Rodgers: Enigma follows the Jets signal caller as he attempts to return from the torn Achilles he suffered during the first game of the 23-24 season. The three-part series also, per Netflix, “explores his life and career through the intimate and difficult parts that made him a household name on and off the field.” If you’re a fan of the iconic Madden football video game series, Prime Video’s It’s In The Game: Madden NFL is an absorbing look at how the groundbreaking franchise became a video game staple. But let’s get back to Thursday Night Football , shall we? Here’s how to stream tonight’s matchup between the Seattle Seahawks and Chicago Bears. Who’s Playing Thursday Night Football Tonight? Tonight’s TNF matchup is a clash between the Seahawks and Bears. What Time/Channel Is Thursday Night Football On Tonight? The Bears-Charge game begins at 8:15 p.m. ET on Prime Video . Pregame coverage starts at 7:00 p.m. ET. Where To Watch Tonight’s Thursday Night Football Game: Amazon Prime is available for $14.99/month or $139/year, with a standalone Prime Video membership also an option for $8.99/month . An ad-free version is available for an additional $2.99/month . Finally, Amazon offers a discounted student option for $7.49/month or $69/year, and EBT, Medicaid, SNAP, and other select government assistance recipients can qualify for a reduced $6.99/month membership. Does Prime Video Offer A Free Trial? Yes! You can sample the service by taking advantage of Prime Video’s 30-day free trial . Thursday Night Football NFL+ Streaming Options: You can stream Sunday afternoon games as well as Thursday, Sunday , and Monday Night Football via NFL+ ($6.99/month).Hungry Sabalenka Ready For More Grand Slam Success

Sister of Quebec man killed in Florida boat explosion also injured, friend says

Manmohan Singh a great listener spoke only substance Former RBI guv Subbarao